Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Rigel Pharmaceuticals stock in Canada | $3.72
Own Rigel Pharmaceuticals shares in just a few minutes.
Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals stocks (RIGL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.19 – an increase of 4.2% over the previous week. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around $133.9 million.
How to buy Rigel Pharmaceuticals stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: RIGL in this case.
- Research Rigel Pharmaceuticals stocks. The platform should provide the latest information available.
- Buy your Rigel Pharmaceuticals stocks. It's that simple.
What's in this guide?
- Can I buy shares in Rigel Pharmaceuticals?
- Has coronavirus impacted Rigel Pharmaceuticals shares?
- Rigel Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Rigel Pharmaceuticals stock a buy or sell?
- Rigel Pharmaceuticals performance over time
- Can I short Rigel Pharmaceuticals shares?
- Rigel Pharmaceuticals's financials
- How volatile are Rigel Pharmaceuticals shares?
- Does Rigel Pharmaceuticals pay a dividend?
- Have Rigel Pharmaceuticals shares ever split?
- Other common questions
How has Coronavirus impacted Rigel Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Rigel Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $3.72, which is 38.17% up on its pre-crash value of $2.3 and 202.44% up on the lowest point reached during the March crash when the stocks fell as low as $1.23.
If you had bought $1,000 worth of Rigel Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $612.43 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,593.16.
Rigel Pharmaceuticals stock priceUse our graph to track the performance of RIGL stocks over time.
Rigel Pharmaceuticals stocks at a glance
|Latest market close||$3.72|
|52-week range||$2.14 - $5.5|
|50-day moving average||$4.2132|
|200-day moving average||$3.9024|
|Wall St. target price||$8.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.352|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Rigel Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Rigel Pharmaceuticals price performance over time
|1 month (2021-06-25)||-18.06%|
|3 months (2021-04-26)||-4.62%|
Rigel Pharmaceuticals financials
|Revenue TTM||USD$133.9 million|
|Gross profit TTM||USD$47.6 million|
|Return on assets TTM||-2.87%|
|Return on equity TTM||-14.65%|
|Market capitalisation||USD$711.3 million|
TTM: trailing 12 months
How to short and sell Rigel Pharmaceuticals stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "RIGL.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 21.6 million Rigel Pharmaceuticals stocks held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 11% down from 24.3 million last month.
There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals stocks can be evaluated.
Rigel Pharmaceuticals's "short interest ratio" (SIR)
Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals stocks currently shorted divided by the average quantity of Rigel Pharmaceuticals stocks traded daily (recently around 2.3 million). Rigel Pharmaceuticals's SIR currently stands at 9.47. In other words for every 100,000 Rigel Pharmaceuticals stocks traded daily on the market, roughly 9470 stocks are currently held short.
However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals stocks, or, against the total number of tradable Rigel Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding stocks (for every 100,000 Rigel Pharmaceuticals stocks in existence, roughly 130 stocks are currently held short) or 0.1273% of the tradable stocks (for every 100,000 tradable Rigel Pharmaceuticals stocks, roughly 127 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Rigel Pharmaceuticals.
Find out more about how you can short Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals stock dividends
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Have Rigel Pharmaceuticals stocks ever split?
Rigel Pharmaceuticals stocks were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals stocks – just the quantity. However, indirectly, the new 800% higher stock price could have impacted the market appetite for Rigel Pharmaceuticals stocks which in turn could have impacted Rigel Pharmaceuticals's stock price.
Rigel Pharmaceuticals stock price volatility
Over the last 12 months, Rigel Pharmaceuticals's stocks have ranged in value from as little as $2.14 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.506. This would suggest that Rigel Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals overview
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Stocks similar to Rigel Pharmaceuticals
Rigel Pharmaceuticals in the news
3 Biotech Stocks That Could Rocket Higher
First Week of March 2022 Options Trading For Rigel Pharmaceuticals (RIGL)
New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
Frequently asked questions
More guides on Finder
How to buy Zevia PBC (ZVIA) stock in Canada
Everything we know about the Zevia PBC IPO, plus information on how to buy in.
How to buy Xponential Fitness (XPOF) stock in Canada
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
How to buy SOPHiA Genetics (SOPH) stock in Canada
Everything we know about the SOPHiA Genetics IPO, plus information on how to buy in.
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
How to buy Core & Main (CNM) stock in Canada
Everything we know about the Core & Main IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.